Research programme: biosimilars - Aurobindo Pharma
Latest Information Update: 28 Mar 2021
At a glance
- Originator TL Biopharmaceutical
- Developer Aurobindo Pharma
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer